Contents

Series Editors Preface *xi*
Volume Editor's Preface *xv*

1 Flow Chemistry at the Extremes: Turning Complex Reactions into Scalable Processes *1*
Andrew R. Bogdan
1.1 Introduction *1*
1.2 Temperature Extremes *2*
1.2.1 Cryogenic Flow Chemistry *2*
1.2.1.1 Organolithium Chemistry in Flow *3*
1.2.1.2 Cyanation *10*
1.2.2 High-Temperature Flow Chemistry *10*
1.3 *In Situ* Use of Hazardous Reagents *14*
1.3.1 Vilsmeier Reagent *15*
1.3.2 Phosgene *16*
1.3.3 Diazomethane *17*
1.4 Photochemistry on Scale *20*
1.5 Conclusion and Outlook *25*
References *26*

2 Automated Flow Chemistry Platforms *33*
Juan A. Rincón, María José Nieves-Remacha, and Carlos Mateos
2.1 Introduction *33*
2.2 Analytical Techniques *33*
2.2.1 In-line NMR Monitoring *34*
2.2.2 In-line Infrared Spectroscopy (IR) *35*
2.2.3 Online HPLC and GC Sampling *35*
2.2.4 UV/Vis Spectroscopy *37*
2.2.5 Other Analytical Techniques *37*
2.2.5.1 Online Mass Spectroscopy *37*
2.2.5.2 In-line Raman Spectroscopy *38*
2.2.6 Future Opportunities *38*
2.3 Automation *38*
2.3.1 High-Throughput Screening Platforms *38*

2.3.2 Integrated Chemistry and Bioactivity Screening Platforms *39*
2.3.3 Flexible and Modular Automated Platforms *43*
2.3.3.1 Robotic Platform for Synthesis in Flow Informed by AI Planning *44*
2.3.3.2 Reconfigurable System for Automated Optimization of Diverse Chemical Reactions *44*
2.3.3.3 OpenFlowChem as a Flexible Software Platform *49*
2.3.3.4 Internet-Based Software Platform *50*
2.3.3.5 Other Platforms *51*
2.3.4 Self-Optimization Algorithms *52*
2.4 Summary and Future Perspective *60*
References *60*

3 Flow Chemistry Opportunities for Drug Discovery *67*
María Lourdes Linares, Enol López, Eduardo Palao, and Jesús Alcázar
3.1 Introduction *67*
3.1.1 Drug Discovery *67*
3.1.2 Flow Chemistry *68*
3.1.3 Merging Flow Chemistry and Drug Discovery *69*
3.2 Current Drug Discovery Toolkit *70*
3.2.1 Reactions for C-Heteroatom Bond Formation *70*
3.2.2 Reactions for C—C Bond Formation *75*
3.2.3 Heterocyclic Synthesis *76*
3.3 Expanding Drug Discovery Toolkit Through Flow Chemistry *80*
3.3.1 Handling Hazardous and Unstable Reagents *80*
3.3.2 Combining Flow with Emerging Technologies *85*
3.3.2.1 Photochemistry *85*
3.3.2.2 Electrochemistry *88*
3.4 Automated Flow Synthesis *90*
3.5 Integrated Platforms *93*
3.6 Conclusions and Outlook *95*
References *95*

4 Flow Chemistry in Medicinal Chemistry: Applications to Bcr-Abl Kinase Inhibitors *103*
Paul Richardson
4.1 Introduction *103*
4.2 Discovery of Imatinib *105*
4.3 Ley Flow Synthesis of Imatinib *106*
4.4 Buchwald Flow Synthesis of Imatinib *121*
4.5 Jamison Flow Synthesis of Imatinib *128*
4.6 "Hybrid Approach" to Imatinib *135*
4.7 Closed-Loop Discovery *140*
4.8 Identification of Novel Bcr-Abl Kinase Inhibitors Through Closed-Loop Discovery *144*
4.9 Conclusion *154*
References *154*

5 Integrated Systems for Continuous Synthesis and Biological Screenings *159*
Antimo Gioiello, Giada Moroni, and Bruno Cerra
5.1 Introduction: Continuous-Flow Technology to Power Medicinal Chemistry *159*
5.2 Equipment, Automated Systems, and Methods for Flow-Based Medicinal Chemistry *161*
5.2.1 Continuous-Flow Synthesis Machines *162*
5.2.2 Process Analytical Technology (PAT) for Effective Integration of Synthesis and Biological Screenings in Continuous Flow *164*
5.2.3 Bioassays for In-line Compound Screening *164*
5.2.4 General Concepts for Automation, Remote Control, and Software Application to Integrated Systems *168*
5.3 Flow Strategies for Building Bioactive Compound Libraries *169*
5.3.1 Click Chemistry *169*
5.3.2 Multicomponent Reactions (MCRs) *174*
5.3.3 Linear and Multistep Synthesis *177*
5.4 End-to-End Autonomous Discovery Platforms *181*
5.5 Conclusions and Future Outlook *191*
References *191*

6 Application of Continuous-Flow Processing in Multistep API and Drug Syntheses *199*
Faith M. Akwi and Paul Watts
6.1 Introduction *199*
6.2 Antibacterial Agents *200*
6.2.1 Ciprofloxacin *200*
6.2.2 Linezolid *201*
6.2.3 Cefotaxime *202*
6.2.4 Rifampicin *203*
6.3 Anticancer Agents *205*
6.3.1 Lomustine *205*
6.3.2 Imatinib *205*
6.4 Antifungal Agents *207*
6.4.1 Fluconazole *207*
6.4.2 Flucytosine *210*
6.5 Anti-HIV Agents *210*
6.5.1 (*R*)-Propylene Carbonate: An Intermediate Toward Anti-HIV Drug, Tenofovir *210*
6.5.2 Dolutegravir *211*
6.5.3 Lamivudine *214*
6.5.4 Efavirenz *215*
6.6 Serotonin Modulators and Stimulators *216*
6.6.1 Flibanserin *216*
6.6.2 Vortioxetine *217*

6.6.3 Melitracen HCl *218*
6.7 Cholinesterase Inhibitor *219*
6.7.1 Donepezil *219*
6.8 Antimalarial Agent *220*
6.8.1 Hydroxychloroquine *220*
6.9 Non-peptide Angiotensin II Receptor Blocker *221*
6.9.1 Valsartan *221*
6.10 Cystic Fibrosis Transmembrane Conductance Regulator *223*
6.10.1 Ivacaftor *223*
6.11 Non-steroidal Anti-inflammatory Agent *224*
6.11.1 Ibuprofen *224*
6.12 Conclusion *226*
References *226*

7 Continuous-Flow Multistep Synthesis of Active Pharmaceutical Ingredients *233*
Yuesu Chen and Jean-Christophe M. Monbaliu
7.1 Introduction *233*
7.2 Generators of Small Molecule Reagents *234*
7.3 Two-Step Flow Synthesis *237*
7.3.1 Clausine C Derivatives *240*
7.3.2 Amino Alcohol APIs from Glycerol *240*
7.3.3 Oxymorphone *242*
7.3.4 Hydroxychloroquine *243*
7.4 Linear Multistep Flow Synthesis *243*
7.4.1 Valsartan Precursor *246*
7.4.2 Eflornithine *246*
7.4.3 Ketamine *249*
7.4.4 Lesinurad *251*
7.5 Convergent Multistep Flow Synthesis *252*
7.5.1 A Histone Deacetylase Inhibitor Precursor *252*
7.5.2 Linezolid *252*
7.6 Advanced Technologies for Multistep Flow Synthesis *255*
7.6.1 Sensors and In-line Analysis *255*
7.6.2 Process Analytical Technology (PAT) *256*
7.6.3 Self-optimization *256*
7.6.4 Modular Flow System *260*
7.6.5 Toward Full Automation *261*
7.7 Conclusion *263*
References *263*

8 Enantioselective (Bio)Catalysis in Continuous-flow as Efficient Tool for the Synthesis of Advanced Intermediates and Active Pharmaceutical Ingredients *269*
Laura Amenós, Anna M. Sobolewska, Esther Alza, and Miquel A. Pericàs
8.1 Introduction *269*
8.2 Homogeneous Enantioselective Catalysis in Continuous Flow *270*

8.2.1 Homogeneous Enantioselective Organocatalysis *271*
8.2.1.1 Enantioselective Michael Addition *271*
8.2.1.2 Enantioselective Aldol Reaction *272*
8.2.1.3 Enantioselective Photooxygenation *272*
8.2.1.4 Enantioselective Imine Reduction *274*
8.2.2 Organometallic Enantioselective Catalysis *275*
8.2.2.1 Enantioselective Sulfoxidation *275*
8.2.2.2 Enantioselective Epoxidation *276*
8.2.2.3 Enantioselective Hydrogenation *277*
8.2.2.4 Enantioselective Michael Addition *279*
8.3 Heterogeneous Enantioselective Catalysis in Flow *280*
8.3.1 Supported Organocatalysts *281*
8.3.1.1 Enantioselective Allylation of Aldehydes *281*
8.3.1.2 Enantioselective α-Amination *282*
8.3.1.3 Enantioselective Arylation of Aldehydes *282*
8.3.1.4 Enantioselective Cyclopropanation *283*
8.3.1.5 Enantioselective Michael Reaction *284*
8.3.1.6 Enantioselective Tandem Michael Addition/Cyclization Reactions *286*
8.3.1.7 Enantioselective Reduction of Imines *288*
8.3.2 Supported Organometallic Catalysts *289*
8.3.2.1 Enantioselective Hydrogenation *289*
8.3.2.2 Enantioselective Hydroformylation *291*
8.3.2.3 Enantioselective 1,4-Addition to Enone *293*
8.3.2.4 Enantioselective Nitroaldol Reaction *294*
8.4 Enantioselective Biocatalysis in Flow *295*
8.5 Asymmetric Total Synthesis in Continuous Flow *298*
8.6 Conclusions *304*
References *304*

9 Innovative Process Development of Pharmaceutical Intermediates Under Continuous-Flow System *311*
Koji Machida and Hiroaki Yasukouchi
9.1 Introduction *311*
9.2 Plug Flow Reactor System for Phosgenation Reaction *312*
9.2.1 Introduction *312*
9.2.2 Feasibility Study *313*
9.2.3 Establishment and Development of Continuous-Flow Process for API Synthesis *314*
9.3 Simple and Practical Packed-Bed Reactor System for Catalytic Reactions *317*
9.3.1 Introduction *317*
9.3.2 Deacylation Reaction with Anion-Exchange Resin *318*
9.3.2.1 Feasibility Study *318*
9.3.2.2 Application for Pharmaceutical Intermediates and Scale-up *319*
9.3.3 Reductive Amination with Biocatalyst *322*

9.4 Flow Reactor Facility for Large-Scale Production *326*
9.4.1 Concept of Our Flow Reactor System *326*
9.4.2 Commercial Production *328*
9.5 Conclusions *328*
References *329*

Index *333*